Spero Therapeutics Inc. (SPRO) is approaching a key regulatory moment, with the FDA set to rule on Tebipenem HBr on June 18, 2026. The drug, developed as an oral carbapenem antibiotic, is being reviewed for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis—conditions that often require hospital-based IV therapy.
Tebipenem pivoxil hydrobromide is designed to offer a potent oral alternative for patients who currently rely on intravenous carbapenem, a shift that could ease hospital burden and improve access to treatment as antibiotic resistance continues to rise.
Background: Prior FDA Rejection and Resubmission
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: contact editorial@rttnews.com